Prescient Therapeutics Hits Enrolment Threshold for PTX-100 Phase 2a Trial Review
Prescient Therapeutics hits enrolment milestone: PTX-100 Phase 2a reaches 20 evaluable patients; first Dose Optimisation...
Prescient Therapeutics hits enrolment milestone: PTX-100 Phase 2a reaches 20 evaluable patients; first Dose Optimisation...
Prescient advances PTX-100 in Phase 2a for CTCL; DOC review set for Dec 2026 as...
Small Caps speaks with Prescient Therapeutics (ASX: PTX) for a general company update focused on...
rescient Therapeutics (ASX: PTX) is advancing PTX100, a first-in-class oncology asset being evaluated in cutaneous...
Prescient Therapeutics’ PTX-100 nears pivotal Phase 2a in CTCL; 100% clinical benefit in Phase 1b...
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug...
Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for...
In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX),...
In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX),...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) is looking to disrupt a US$1.8 billion market on the...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.